Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.52 |
| ▸ | AVPR1B | P47901 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | NMT1 | P30419 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16502981 | 0.85 | F2 (0.68) | F2L3MBTL1AVPR1AAVPR1BALDH1A1 | |
| SCHEMBL4516501 | 0.81 | F2 (0.55) | F2L3MBTL1TDP1AVPR1AAVPR1B | |
| SCHEMBL4514428 | 0.80 | L3MBTL1 (0.83) | L3MBTL1TDP1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL13940302 | 0.79 | NMT1 (0.51) | F2L3MBTL1AVPR1AAVPR1BALDH1A1 | |
| SCHEMBL4515569 | 0.79 | NR3C1 (0.68) | F2L3MBTL1AVPR1BALDH1A1POLB | |
| SCHEMBL4080617 | 0.78 | F2 (0.56) | F2AVPR1AAVPR1BALDH1A1NMT1 | |
| SCHEMBL23752436 | 0.75 | F2 (1.00) | F2AVPR1AAVPR1BNMT1 | |
| SCHEMBL23752437 | 0.75 | F2 (1.00) | F2AVPR1AAVPR1BNMT1 | |
| SCHEMBL16509566 | 0.75 | NMT1 (0.62) | F2AVPR1BALDH1A1SMN1; SMN2NMT1 | |
| SCHEMBL3450185 | 0.74 | F2 (0.53) | F2AVPR1AAVPR1BNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| EP-1807391-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046916-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | F2 3409/4885L3MBTL1 4844/4885TDP1 4569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.